The sterile medical packaging market size is calculated at USD 63.85 billion in 2024 and is projected to reach around USD 182.13 billion by 2034. The market is expanding at a CAGR of 11.05% between 2024 and 2034.

| Metric | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | TTM |
| Total revenue | 2.86 B | 2.79 B | 3.05 B | 3.08 B | 2.89 B | 2.89 B | 3.14 B | 3.20 B | 12.13 B |
| YoY growth | −4.99% | −6.32% | −1.58% | 0.62% | 1.19% | 3.66% | 2.91% | 3.96% | — |
| Cost of goods sold | −2.36 B | −2.35 B | −2.50 B | −2.50 B | −2.36 B | −2.38 B | −2.55 B | −2.59 B | −9.87 B |
| Gross profit | 498.00 M | 434.00 M | 552.00 M | 583.00 M | 534.00 M | 514.00 M | 596.00 M | 617.00 M | 2.26 B |
| YoY growth | 25.76% | −2.47% | 4.74% | 10.42% | 7.23% | 18.43% | 7.97% | 5.83% | — |
| Operating expenses (excl. COGS) | −145.00 M | −154.00 M | −150.00 M | −146.00 M | −147.00 M | −152.00 M | −161.00 M | −155.00 M | −615.00 M |
| Operating income | 353.00 M | 280.00 M | 402.00 M | 437.00 M | 387.00 M | 362.00 M | 435.00 M | 462.00 M | 1.65 B |
| YoY growth | 36.29% | −1.75% | 6.07% | 9.52% | 9.63% | 29.29% | 8.21% | 5.72% | — |
| Non-operating income (total) | −210.00 M | −146.00 M | −137.00 M | −614.00 M | 134.00 M | −90.00 M | −142.00 M | −140.00 M | −238.00 M |
| Pretax income | 143.00 M | 134.00 M | 265.00 M | −177.00 M | 521.00 M | 272.00 M | 293.00 M | 322.00 M | 1.41 B |
| YoY growth | −0.69% | −16.77% | 10.88% | −170.24% | 264.34% | 102.99% | 10.57% | — | — |
| Equity in earnings | −6.00 M | −1.00 M | −4.00 M | 6.00 M | −1.00 M | 1.00 M | 1.00 M | 1.00 M | 2.00 M |
| Taxes | −59.00 M | −40.00 M | −54.00 M | 39.00 M | −128.00 M | −46.00 M | −78.00 M | −84.00 M | −336.00 M |
| Non-controlling/minority interest | −46.00 M | −26.00 M | −33.00 M | −43.00 M | −34.00 M | −34.00 M | −35.00 M | −25.00 M | −128.00 M |
| After tax other income/expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |
| Net income before discontinued operations | 32.00 M | 67.00 M | 174.00 M | −175.00 M | 358.00 M | 193.00 M | 181.00 M | 214.00 M | 946.00 M |
| Discontinued operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |
| Net income | 32.00 M | 67.00 M | 174.00 M | −175.00 M | 358.00 M | 193.00 M | 181.00 M | 214.00 M | 946.00 M |
| YoY growth | −64.04% | −34.31% | 10.83% | −210.06% | 1018.75% | 188.06% | 4.02% | — | — |
| Dilution adjustment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |
| Preferred dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |
| Diluted net income available to common stockholders | 32.00 M | 67.00 M | 174.00 M | −175.00 M | 358.00 M | 193.00 M | 181.00 M | 214.00 M | 946.00 M |
| Basic earnings per share (basic EPS) | 0.27 | 0.56 | 1.45 | −1.47 | 3.03 | 1.65 | 1.57 | 1.86 | 8.11 |
| YoY growth | −64.15% | −34.53% | 10.64% | −210.25% | 1030.06% | 195.22% | 7.90% | — | — |
| Diluted earnings per share (diluted EPS) | 0.27 | 0.56 | 1.45 | −1.47 | 3.02 | 1.65 | 1.56 | 1.85 | 8.08 |
| YoY growth | −64.12% | −34.42% | 10.64% | −210.43% | 1029.72% | 194.94% | 7.61% | — | — |
| Average basic shares outstanding | 119.51 M | 119.60 M | 119.60 M | 119.30 M | 118.30 M | 116.70 M | 115.30 M | 115.20 M | — |
| Diluted shares outstanding | 119.74 M | 119.80 M | 119.80 M | 119.30 M | 118.60 M | 117.00 M | 115.80 M | 115.70 M | — |
| EBITDA | 480.00 M | 395.00 M | 517.00 M | 551.00 M | 491.00 M | 472.00 M | 549.00 M | 578.00 M | 2.09 B |
| YoY growth | 28.69% | −3.19% | 2.58% | 5.35% | 2.29% | 19.49% | 6.19% | 4.90% | — |
| EBIT | 353.00 M | 280.00 M | 402.00 M | 437.00 M | 387.00 M | 362.00 M | 435.00 M | 462.00 M | 1.65 B |
| YoY growth | 36.29% | −1.75% | 6.07% | 9.52% | 9.63% | 29.29% | 8.21% | 5.72% | — |
| Total operating expenses | −2.51 B | −2.51 B | −2.65 B | −2.65 B | −2.51 B | −2.53 B | −2.71 B | −2.74 B | −10.48 B |